Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05557838
PHASE3

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.

Official title: An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2023-02-22

Completion Date

2025-03-31

Last Updated

2025-02-07

Healthy Volunteers

No

Interventions

DRUG

Durvalumab

Durvalumab IV (intravenous infusion)

DRUG

Tremelimumab

Tremelimumab IV (intravenous infusion)

Locations (32)

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changsha, China

Research Site

Changsha, China

Research Site

Chengdu, China

Research Site

Fuzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Jinan, China

Research Site

Nanjing, China

Research Site

Nanjing, China

Research Site

Nanjing, China

Research Site

Ningbo, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Tianjin, China

Research Site

Tianjin, China

Research Site

Tianjin, China

Research Site

Wenzhou, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Zhangjiagang, China

Research Site

Zhengzhou, China

Research Site

Zhengzhou, China